Lopinavir/ritonavir cuts malaria risk in children with HIV
GS-7977 plus ribavirin rapidly suppresses HCV but most patients relapse
Telaprevir and boceprevir boost sustained response rates for HIV/HCV coinfected
Hormonal contraception and HIV risk in women: more evidence but uncertainty remains
Once-a-month HIV drug maintains good levels for prevention; few side-effects so far
Four doses of PrEP a week may be enough to protect
A tale of two trials: how adherence is everything in PrEP
